Medical Imaging Information Systems Market

Executive Summary

Medical Imaging Information Systems Market was valued at US $40.43 billion in 2021 and is projected to grow at 6.47% CAGR over the forecast period to reach US $58.90 billion by 2027. Medical Imaging Information Systems Market represented US $4.77 billion opportunity over 2019-2021 and estimated to create US $18.47 billion opportunity in 2027 over 2021.

Medical Imaging Information Systems from Consainsights analyses the Medical Imaging Information Systems Market in the Life Sciences industry over the forecast period to 2027.

Medical Imaging Information Systems research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Medical Imaging Information Systems segmentation includes Modality, Software and Geography.

Based on the Modality, the Medical Imaging Information Systems analysis covers COMPUTED TOMOGRAPHY (CT), MAGNETIC RESONANCE IMAGING (MRI), POSITRON EMISSION TOMOGRAPHY (PET), PET-CT, ULTRASOUND, X-RAY, BIOMARKERS.

In Modality segment, COMPUTED TOMOGRAPHY (CT) segment has highest cagr growth of 5.73%.

Based on the Software, the Medical Imaging Information Systems analysis covers INTEGRATED RIS/PACS, HOSPITAL INFORMATION SYSTEMS, SPECIALTY SOFTWARE.

In Software segment, INTEGRATED RIS/PACS segment has highest cagr growth of 5.73%.

Based on the region, the Medical Imaging Information Systems analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include ESAOTE S.P.A., FONAR CORP., FUJIFILM CORP., FUJIFILM SONOSITE INC., GE HEALTHCARE, HITACHI MEDICAL CORP., HOLOGIC INC., MINDRAY MEDICAL INTERNATIONAL LTD., NEUSOFT MEDICAL SYSTEMS CO. LTD., PARAMED MEDICAL SYSTEMS INC. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Modality

Introduction

In 2021, COMPUTED TOMOGRAPHY (CT) segment has the highest revenue of US $15.44 billion and is expected to grow at CAGR of 5.73% by 2027 COMPUTED TOMOGRAPHY (CT) segment has highest cagr growth of 5.73%.

COMPUTED TOMOGRAPHY (CT)

COMPUTED TOMOGRAPHY (CT) segment was valued at US $13.62 billion in 2019 and is projected to grow at 5.73% CAGR over the forecast period to reach US $22.49 billion by 2027. COMPUTED TOMOGRAPHY (CT) segment represented US $1.82 billion opportunity over 2019-2021 and estimated to create US $7.05 billion opportunity in 2027 over 2021.

MAGNETIC RESONANCE IMAGING (MRI)

MAGNETIC RESONANCE IMAGING (MRI) segment was valued at US $8.39 billion in 2019 and is projected to grow at 5.73% CAGR over the forecast period to reach US $13.85 billion by 2027. MAGNETIC RESONANCE IMAGING (MRI) segment represented US $1.12 billion opportunity over 2019-2021 and estimated to create US $4.34 billion opportunity in 2027 over 2021.

POSITRON EMISSION TOMOGRAPHY (PET)

POSITRON EMISSION TOMOGRAPHY (PET) segment was valued at US $5.00 billion in 2019 and is projected to grow at 5.73% CAGR over the forecast period to reach US $8.25 billion by 2027. POSITRON EMISSION TOMOGRAPHY (PET) segment represented US $0.67 billion opportunity over 2019-2021 and estimated to create US $2.59 billion opportunity in 2027 over 2021.

PET-CT

PET-CT segment was valued at US $4.02 billion in 2019 and is projected to grow at 5.73% CAGR over the forecast period to reach US $6.64 billion by 2027. PET-CT segment represented US $0.54 billion opportunity over 2019-2021 and estimated to create US $2.08 billion opportunity in 2027 over 2021.

ULTRASOUND

ULTRASOUND segment was valued at US $2.22 billion in 2019 and is projected to grow at 5.73% CAGR over the forecast period to reach US $3.66 billion by 2027. ULTRASOUND segment represented US $0.30 billion opportunity over 2019-2021 and estimated to create US $1.15 billion opportunity in 2027 over 2021.

X-RAY

X-RAY segment was valued at US $1.67 billion in 2019 and is projected to grow at 5.73% CAGR over the forecast period to reach US $2.76 billion by 2027. X-RAY segment represented US $0.22 billion opportunity over 2019-2021 and estimated to create US $0.87 billion opportunity in 2027 over 2021.

BIOMARKERS

BIOMARKERS segment was valued at US $0.75 billion in 2019 and is projected to grow at 5.73% CAGR over the forecast period to reach US $1.24 billion by 2027. BIOMARKERS segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.39 billion opportunity in 2027 over 2021.

Software

Introduction

In 2021, INTEGRATED RIS/PACS segment has the highest revenue of US $17.29 billion and is expected to grow at CAGR of 5.73% by 2027 INTEGRATED RIS/PACS segment has highest cagr growth of 5.73%.

INTEGRATED RIS/PACS

INTEGRATED RIS/PACS segment was valued at US $15.25 billion in 2019 and is projected to grow at 5.73% CAGR over the forecast period to reach US $25.19 billion by 2027. INTEGRATED RIS/PACS segment represented US $2.04 billion opportunity over 2019-2021 and estimated to create US $7.90 billion opportunity in 2027 over 2021.

HOSPITAL INFORMATION SYSTEMS

HOSPITAL INFORMATION SYSTEMS segment was valued at US $14.37 billion in 2019 and is projected to grow at 5.73% CAGR over the forecast period to reach US $23.74 billion by 2027. HOSPITAL INFORMATION SYSTEMS segment represented US $1.92 billion opportunity over 2019-2021 and estimated to create US $7.44 billion opportunity in 2027 over 2021.

SPECIALTY SOFTWARE

SPECIALTY SOFTWARE segment was valued at US $6.04 billion in 2019 and is projected to grow at 5.73% CAGR over the forecast period to reach US $9.97 billion by 2027. SPECIALTY SOFTWARE segment represented US $0.81 billion opportunity over 2019-2021 and estimated to create US $3.13 billion opportunity in 2027 over 2021.